Anji Pharmaceuticals
Brian Hubbard has over 20 years of experience in the pharmaceutical industry. Brian is currently the Chief Executive Officer at Anji Pharma and a Partner at Sprout BioVentures, both since 2018. Previously, they served as the Chief Executive Officer at Dogma Therapeutics from 2015 to 2020. Prior to that, they held various roles at Broad Institute from 2011 to 2015, including Director of Therapeutics Projects and Director of Therapeutics Discovery & Development. Brian also worked as the Sr. Director of Cardiovascular Diseases at Merck from 2008 to 2011 and as the Director of Cardiovascular and Metabolism at Novartis Institutes for Biomedical Research from 2002 to 2008. Brian started their career at Millennium Pharmaceuticals in 2000, focusing on metabolic diseases.
Brian Hubbard earned their Bachelor's degree in Chemistry from William & Mary, completing their studies from 1990 to 1994. Brian then pursued further education, completing their Ph.D. in Chemistry from the University of Illinois Urbana-Champaign. Afterward, Brian continued their studies at Harvard Medical School, specializing in Biochemistry and Antibiotics during their Post Doctoral program.
This person is not in any teams
Anji Pharmaceuticals
Anji Pharmaceuticals is focused on tackling high-value targets validated by human genetics. We are exhaustive in our discovery and clinical efforts while nimble in our strategy and execution. We have assembled a world-class team of scientist entrepreneurs who are committed to accelerate innovative medicines in China and worldwide.